|
Friday, December 6, 2024, San Diego, California, 3:15 PM – 5:15 PM PT (6:15 PM – 8:15 PM ET)
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid LeukemiaA CME Friday Satellite Symposium and Webcast Preceding the 66th ASH Annual Meeting
Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks 3:15 PM – 5:15 PM — Educational Meeting Location Manchester Grand Hyatt San Diego 1 Market Place San Diego, California Meeting Room Seaport A-D (Second Level) Faculty
Alexander Perl, MD Associate Professor of Medicine Perelman School of Medicine Member, Leukemia Program Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Richard M Stone, MD Lunder Family Chair in Leukemia Chief of Staff Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Boston, Massachusetts Eunice S Wang, MD Chief, Leukemia/Benign Hematology Service Professor of Oncology, Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo, New York Andrew H Wei, MBBS, PhD Professor, Department of Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital University of Melbourne Walter and Eliza Hall Institute of Medical Research Melbourne, Australia Moderator Eytan M Stein, MD Chief, Leukemia Service Director, Program for Drug Development in Leukemia Associate Attending Physician Leukemia Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York This activity is supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.
Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks 3:15 PM – 5:15 PM — Educational Meeting MODULE 1: Treatment for Older Patients with Acute Myeloid Leukemia (AML) — Prof Wei
MODULE 2: Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML (sAML) — Dr Stone
MODULE 3: Role of FLT3 Inhibitors in AML Management — Dr Perl
MODULE 4: Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Stein
MODULE 5: Potential Role of Menin Inhibitors and Other Novel Agents in the Treatment of AML — Dr Wang
Target Audience
CE Credit FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Perl — Advisory Committees: Aptose Biosciences, Astellas, Bristol Myers Squibb, Curis Inc, Daiichi Sankyo Inc, Rigel Pharmaceuticals Inc, Schrödinger, Syndax Pharmaceuticals; Consulting Agreements: Astellas, Daiichi Sankyo Inc, Foghorn Therapeutics; Contracted Research: Astellas, Daiichi Sankyo Inc, Syndax Pharmaceuticals; Data and Safety Monitoring Board/Committee: Foghorn Therapeutics; Nonrelevant Financial Relationships: Beat AML LLC, Leukemia & Lymphoma Society. Dr Stone — Consulting Agreements: AbbVie Inc, Amgen Inc, Aptevo Therapeutics, AvenCell, BerGenBio ASA, Bristol Myers Squibb, Cellarity, CTI BioPharma, a Sobi Company, Curis Inc, Daiichi Sankyo Inc, Ensem Therapeutics, GlycoMimetics Inc, GSK, Hemavant, Jazz Pharmaceuticals Inc, Kura Oncology, LAVA Therapeutics, Ligand Pharmaceuticals, Redona Therapeutics, Rigel Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Aptevo Therapeutics, Ipsen Biopharmaceuticals Inc, Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc. Dr Wang — Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Gilead Sciences Inc, GSK, ImmunoGen Inc, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Kura Oncology, Novartis, QIAGEN, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Schrödinger, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Consulting Agreement: Kura Oncology; Contracted Research: Arog Pharmaceuticals Inc, Astellas, Biomea Fusion, Cellectis, ImmunoGen Inc, Kura Oncology, Pfizer Inc, Precigen Inc, Sumitomo Dainippon Pharma Oncology Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Gilead Sciences Inc; Speakers Bureaus: Astellas, Daiichi Sankyo Inc, DAVA Oncology, Pfizer Inc; Nonrelevant Financial Relationship: UptoDate (section editor). Prof Wei — Advisory Committees: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Servier Pharmaceuticals LLC; Consulting Agreements: AbbVie Inc, Aculeus Therapeutics, Novartis, Servier Pharmaceuticals LLC, Shoreline Biosciences; Contracted Research: AbbVie Inc, Amgen Inc, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Data and Safety Monitoring Board/Committee: HOVON; Speakers Bureaus: AbbVie Inc, Astellas, Bristol Myers Squibb, Novartis, Servier Pharmaceuticals LLC; Nonrelevant Financial Relationship: Prof Wei is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof Wei receives such a financial benefit. MODERATOR — Dr Stein — Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Contracted Research: Astellas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Syndax Pharmaceuticals. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc. Manchester Grand Hyatt San Diego
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia.
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |